---
title: "Shenzhen Yimufeng Biotechnology Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange"
description: "36Kr has learned that Shenzhen Yimu Feng Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the exclusive sponsor"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275821883.md"
published_at: "2026-02-12T23:21:57.000Z"
---

# Shenzhen Yimufeng Biotechnology Co., Ltd. submitted a listing application to the Hong Kong Stock Exchange

> 36Kr has learned that Shenzhen Yimu Feng Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the exclusive sponsor

36Kr has learned that Shenzhen Yimu Feng Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the exclusive sponsor

### Related Stocks

- [26004.HK - 益方生物科技(上海)股份有限公司](https://longbridge.com/en/quote/26004.HK.md)
- [25229.HK - 福建万辰生物科技集团股份有限公司](https://longbridge.com/en/quote/25229.HK.md)
- [25217.HK - 深圳麦科田生物医疗技术股份有限公司](https://longbridge.com/en/quote/25217.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 3.5 亿首付款、总额达 85 亿美元！信达生物与礼来合作布局肿瘤免疫新药研发 | 信达生物与礼来达成突破性合作，将联合开发肿瘤及免疫新药。此次交易预付款 3.5 亿美元，总额最高达 85 亿美元。双方摒弃传统授权，采用从零开始的共同研发模式，标志着中国药企创新力获全球顶尖药企深度认可，开启全球战略协作新篇章。 | [Link](https://longbridge.com/en/news/275269682.md) |
| 米哈游、阅文、网易托举，卡牌第二梯队冲击上市 | 春节临近，卡牌赛道竞争加剧。卡游成为央视《2026 年春节联欢晚会》独家卡牌合作伙伴，其他品牌也与央视合作。卡牌企业在港交所排队上市，Suplay 已递交招股书。尽管新兴卡牌企业营收远低于卡游，但资本支持和市场细分使其快速成长。上市速度成为 | [Link](https://longbridge.com/en/news/275327133.md) |
| Anthropic 加速 IPO 进程：引入资本老手，最早今年上市 | 为备战 IPO，Anthropic 引入曾主导通用汽车上市的资本老将 Chris Liddell。其兼具特朗普政府任职的政治背景，旨在强化治理以应对监管。公司刚完成 300 亿美元融资，估值达 3800 亿美元，领投方包括 GIC 与 Co | [Link](https://longbridge.com/en/news/275924510.md) |
| 2220 亿美元持续 “输血” AI 赛道，资本正催生一批不盈利的僵尸企业 | 资本过热正催生 AI“僵尸企业”：依赖融资输血、难以盈利。美国 AI 风投占比预计 2025 年将超 65%，但许多公司交付慢、成本高，真实效益被补贴掩盖。资本错配延缓市场出清。随着补贴退潮，无法造血的企业将面临淘汰，具备可持续商业模式的公 | [Link](https://longbridge.com/en/news/275461639.md) |
| 利润向左，净资向右：拆解非上市人身险企业绩的 “面子” 与 “里子” | 2025 年非上市人身险公司净利润大幅增长至 666 亿元，但净资产却缩水近 100 亿元，显示出 “增利不增资” 的结构性背离。综合投资收益率中位数从 8.39% 降至 2.73%。多家险企如中银三星人寿、光大永明人寿等，尽管净利润创历史 | [Link](https://longbridge.com/en/news/275639038.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.